From Chronodisruption to Sarcopenia: The Therapeutic Potential of Melatonin.
José Fernández-MartínezYolanda Ramírez-CasasYang YangPaula Aranda MartínezLaura Martínez-RuizGermaine EscamesDario Acuna-CastroviejoPublished in: Biomolecules (2023)
Sarcopenia is an age-related condition that involves a progressive decline in muscle mass and function, leading to increased risk of falls, frailty, and mortality. Although the exact mechanisms are not fully understood, aging-related processes like inflammation, oxidative stress, reduced mitochondrial capacity, and cell apoptosis contribute to this decline. Disruption of the circadian system with age may initiate these pathways in skeletal muscle, preceding the onset of sarcopenia. At present, there is no pharmacological treatment for sarcopenia, only resistance exercise and proper nutrition may delay its onset. Melatonin, derived from tryptophan, emerges as an exceptional candidate for treating sarcopenia due to its chronobiotic, antioxidant, and anti-inflammatory properties. Its impact on mitochondria and organelle, where it is synthesized and crucial in aging skeletal muscle, further highlights its potential. In this review, we discuss the influence of clock genes in muscular aging, with special reference to peripheral clock genes in the skeletal muscle, as well as their relationship with melatonin, which is proposed as a potential therapy against sarcopenia.
Keyphrases
- skeletal muscle
- oxidative stress
- insulin resistance
- community dwelling
- anti inflammatory
- physical activity
- dna damage
- multiple sclerosis
- gene expression
- stem cells
- cell death
- cell proliferation
- dna methylation
- cardiovascular disease
- cardiovascular events
- adipose tissue
- high intensity
- resistance training
- human health
- coronary artery disease
- risk assessment
- cell therapy
- mesenchymal stem cells
- heat shock protein
- smoking cessation